Surveillance and Follow-up

Goals & Principles of Surveillance - Keeping Tabs Tight

• Core Objectives:
  • Detect recurrence: Local, regional, or distant (metastases).
  • Monitor treatment complications: Short-term & long-term (e.g., limb function, organ toxicity).
  • Evaluate oncologic outcomes: Disease-Free Survival (DFS), Overall Survival (OS).
  • Identify Second Primary Malignancies (SPM).
• Key Principles:
  • Risk-stratified: Based on tumor biology, stage, & prior therapy.
  • Multimodal approach: Clinical assessment, imaging (X-ray, CT, MRI, PET), biomarkers (LDH, ALP).
  • Scheduled follow-up: Intervals decrease over time (e.g., 3-6 months initially, then annually). Lifelong for some.
  • Patient engagement: Crucial for adherence.

⭐ For osteosarcoma, lung metastases are the most common site of recurrence, making regular chest imaging vital.

Follow-up Schedules & Modalities - Scan, See, Secure

Goal: Detect recurrence, metastases, & complications early. Tailored to tumor, grade, stage, treatment.

• Schedules (General):

  • Malignant:
    • Yrs 1-2: Every 3-4 mo.
    • Yrs 3-5: Every 6 mo.

    • 5 Yrs: Annually.

  • Aggressive Benign (e.g., GCT): Similar to low-grade malignant.
  • Benign: Symptom-driven post-healing.

• Modalities - 📌 "Scan, See, Secure":

  • Scan (Imaging):
    • Local: X-ray, MRI (best for local recurrence).
    • Systemic: CT Chest (sarcoma lung mets), Bone Scan. PET-CT for aggressive/equivocal.
  • See (Clinical):
    • Symptoms: Pain, new issues.
    • Exam: Local site, function, neurovascular.
  • Secure (Pathology/Labs):
    • Biopsy: If recurrence suspected.
    • Labs: LDH, ALP, ESR (monitor trends).

⭐ Osteosarcoma most commonly metastasizes to LUNGS, then BONE. Chest imaging is vital.

Tumor-Specific Surveillance Differences - Tailored Tumor Trails

• Osteosarcoma & Ewing Sarcoma:
  • Primary Goal: Detect lung metastases & local recurrence.
  • Chest Imaging: CT chest every 3-6 months for 2-3 yrs, then annually up to 5 yrs (Ewing's may extend to 10 yrs).
  • Local Site: MRI/X-ray every 6 months or as indicated.
  • Ewing's Specific: Consider PET-CT/Whole Body MRI for systemic relapse risk.
• Chondrosarcoma:
  • Primary Goal: Monitor local recurrence; late lung metastases.
  • Local Site: Imaging (X-ray/CT/MRI based on grade) every 6-12 months for 5-10 yrs.
  • Chest: Annual X-ray/CT, especially for high-grade lesions.
• Giant Cell Tumor (GCT):
  • Primary Goal: High local recurrence (~20-50%); benign lung implants.
  • Local Site: X-rays every 3-6 months for 2-3 yrs, then annually for ~5 yrs.
  • Chest: X-ray every 6-12 months for 3-5 yrs.

⭐ GCT lung implants, though termed "metastases", are often histologically benign; surveillance guides management, not always aggressive therapy.

Detecting Recurrence & Long-Term Complications - Bumps & Beyond Care

• Recurrence Detection:
  • Regular clinical exams (pain, swelling).
  • Imaging: X-ray, MRI (local), CT Chest (mets). PET-CT if suspicious.
  • Follow-up: Typically every 3-6 months for 2-5 years, then annually. Biopsy confirms.
• Long-Term Complications:
  • Surgical: Implant issues, limb length discrepancy (LLD), chronic pain.
  • Chemo-related: Cardiotoxicity (e.g., Doxorubicin), nephrotoxicity (e.g., Cisplatin), infertility, secondary malignancy.
  • Radio-related: Pathological fractures, fibrosis, nerve damage, secondary malignancy.
  • Functional & Psychosocial: Reduced mobility, QoL impact; requires rehab & support.

⭐ Osteosarcoma most commonly metastasizes to the lungs; regular chest imaging is vital for early detection.

High‑Yield Points - ⚡ Biggest Takeaways

• Regular follow-up is vital for early detection of local recurrence or distant metastasis.
• Imaging (X-ray, MRI, CT, PET-CT) frequency depends on tumor type, grade, and treatment.
• GCT has high local recurrence; monitor lungs for metastasis (Chest X-ray/CT).
• Osteosarcoma & Ewing's sarcoma need long-term surveillance for late recurrence & second malignancies.
• Benign aggressive tumors also require monitoring for recurrence.
• Serum markers (LDH, ALP) can aid in monitoring osteosarcoma.
• Minimum follow-up is typically 5 years, longer for high-grade sarcomas.